TMCnet News
ArcherDX Launches NGS Assays for Hematological Malignancy ProfilingArcherDX, Inc., announced three new targeted next-generation sequencing assays to capture and identify known and novel gene fusions, point mutations and relative expression levels in myeloid and lymphoid origin malignancies. The new Archer™ FusionPlex™ Blood Cancer panels utilize Archer's proprietary Anchored Multiplex PCR (News - Alert) (AMP™) to detect known and novel fusions from RNA. AMP also tags each input fragment with a barcode for molecular quantification for expression level detection and added confidence in mutation detection. Archer FusionPlex Heme v2, Myeloid and ALL panels each interrogate 80-90 genes, simultaneously detecting fusions, critical point mutations and expression levels when analyzed using the Archer Analysis bioinformatics platform. "We designed these blood cancer panels to target and detect all types of driver mutation events, so that clinical researchers have the most information possible about a tumor sample," said Brian Kudlow, Ph.D., VP o Research and Development at ArcherDX. "Gene fusions are a particularly important class of mutations in hematological malignancies. For example, Ph-like ALL fusions are critical markers for pediatric acute lymphoblastic leukemia; yet, existing methods struggle to detect and provide answers in a timely and multiplex fashion." The assays are the newest additions to the FusionPlex product line, which includes panels for sarcoma and solid tumor mutation profiling. About ArcherDX ArcherDX addresses the bottlenecks associated with using NGS in translational research by offering a robust platform for targeted sequencing applications. By combining proprietary Anchored Multiplexed PCR (AMP) chemistry and easy-to-use, lyophilized reagents, Archer NGS assays generate highly enriched sequencing libraries to detect gene fusions, point mutations, CNVs and RNA abundance. Complemented by the Archer suite of bioinformatics software, ArcherDX technology dramatically enhances complex mutation identification and discovery. ArcherDX is headquartered in Boulder, Colorado. Note: Archer kits and analysis software are for research use only and not for use in diagnostic procedures.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160517005199/en/ |
